Report Code: A12478 | Pages: NA | ||
Tables: NA | Charts: NA |
|
Granisetron is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy and radiotherapy. Its major effect is to reduce the activity of the vagus nerve, the nerve that activates the vomiting center in the medulla oblongata. It controls serotonin from binding to 5-HT3 receptors in the small intestine and prevents the likelihood of nausea and vomiting after chemo or radiation therapy. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors. Granisetron is a well-tolerated drug with few side effects. Headache, dizziness, and constipation are the most commonly reported side effects associated with its use. No significant drug interactions reported with this drug's use. It is broken down by the liver's cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system.
Granisetron was developed by chemists working at the British drug company Beecham in around 1988 (contradictory) and is available as a generic. It is produced by Roche Laboratories under the trade name Kytril. The drug was approved in the UK in 1991 and in U.S. in 1994 by the FDA. Granisetron is metabolized slowly by the liver, giving it a longer than average half-life. One dose usually lasts 4 to 9 hours and is usually administered once or twice daily. This drug is removed from the body by the liver and kidneys. It was patented in 1985 (contradictory) and approved for medical use in 1991.
COVID-19 Impact Analysis
Top Impacting Factors
Market Trends
High healthcare expenditure per capita and favorable medical reimbursement policies in developed nations have contributed to the growth of the granisetron market. Moreover, increase in applications of these drugs in post-operative surgical procedures for the prevention and treatment of nausea and vomiting is likely to boost demand during the forecast period.
Nearly 70% to 80 % of cancer patients are affected by chemotherapy-induced nausea and vomiting (CINV) and 50% to 80% patients are affected by radiation-induced nausea and vomiting (RNIV). Increase in number of patients undergoing chemotherapy and radiation therapy owing to well-established health care facilities, high healthcare expenditure per capita, and favorable medical reimbursement policies in developed nations have contributed to the growth of the granisetron market.
Increased R&D investments by pharmaceutical and biotechnology companies for the development of highly effective and efficient drugs with minimum side effects is projected to fuel demand for granisetron market during the forecast period.
Key Benefits of Report
Questions Answered in the Granisetron Market Report
Granisetron Market Report Highlights
Aspects | Details |
---|---|
By Product Type |
|
By Application |
|
By Distribution Channel |
|
By Region |
|
Key Market Players | Cipla Ltd., Hikma Pharmaceuticals, Fresenius Kabi, Aristo Pharmaceuticals Pvt Ltd., Teva Pharmaceuticals, Kyowa Kirin, Mankind Pharma Ltd., Heron Therapeutics, Wockhardt, Sandoz |
Loading Table Of Content...
Start reading.
This Report and over 71,251+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time for readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save the time of readers